Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical ...
Many of the bispecific antibodies (BsAbs) approved by global regulators have yet to demonstrate robust clinical benefit ...
E22 guideline should incorporate caregiver feedback, according to responses submitted by industry groups and manufacturers to ...
In the latest tranche of published warning letters, the US Food and Drug Administration (FDA) has continued to go after ...
AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion ( STAT) AstraZeneca’s in ...
Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, ...
US Food and Drug Administration (FDA) officials credited recent advancements in regulatory science and flexibilities with ...
A European Medicines Agency (EMA) group has recommended actions the regulator and industry can take to accelerate regulatory ...
The US Food and Drug Administration (FDA) has announced that starting on 1 October 2026, manufacturers must submit adverse ...
The US Food and Drug Administration (FDA) has issued a warning letter to a medical spa company in Texas for violating the ...
Several patient and disease advocacy organizations have responded to the Center for Drug Evaluation and Research's (CDER) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results